Liquidia Technologies to Present New Data Supporting the Role of Particle Size and Shape in Vaccine Development

-Company To Present at the 9th Annual ImVacS, The Immunotherapies and Vaccine Summit August 13th, 2014 Liquidia Technologies today announced that it will present new data demonstrating the influence of tunable PRINT® (Particle Replication In Non-Wetting Templates) particle characteristics on the immune response as a component of vaccine development. Results from this preclinical study will be presented at the 9th Annual ImVacS, …